The Gibco™ LV-MAX™ Transfection Kit is an essential component of the LV-MAX™ Lentiviral Production System, designed for the high-efficiency transient transfection of Gibco Viral Production Cells (high-density, suspension-adapted HEK 293-derived cells). This kit contains a cationic lipid-based transfection reagent, a lentiviral production supplement, and an LV enhancer, all formulated to maximize lentiviral vector production while maintaining cell viability.
With its chemically defined, serum-free, and animal-origin-free formulation, this kit ensures consistent, scalable, and high-yield lentivirus production, achieving titers of up to 1 × 10⁸ TU/mL (unconcentrated LVVs-GFP).
Key Features & Benefits
1. High-Efficiency Lentiviral Production
- Optimized for high-density HEK 293 suspension cell transfection.
- Achieves lentiviral vector titers of up to 1 × 10⁸ TU/mL.
- Delivers higher yields than conventional transfection methods (e.g., PEI-based transfection).
2. Reproducible & Scalable Performance
- Designed for scalable transfection in 96-well plates to 2-L bioreactors.
- Provides high transfection efficiency with minimal toxicity.
- Ensures batch-to-batch consistency for reliable virus production.
3. Serum-Free, Chemically Defined & Animal-Origin-Free
- No animal-derived components, ensuring regulatory compliance.
- Reduces batch variability and potential immunogenic risks.
- Supports high-density cell growth and transfection efficiency.
4. Easy-to-Use & Optimized for Lentivirus Production
- Simplified transfection protocols compatible with transient production workflows.
- Works synergistically with LV-MAX™ Production Medium to enhance viral yield.
- Eliminates the need for additional supplements or optimization steps.
Kit Components & Storage
| Component | Quantity | Storage Conditions |
|---|
| LV-MAX™ Supplement | 50 mL | 2–8°C, protect from light |
| LV-MAX™ Transfection Reagent | 6 mL | 2–8°C, protect from light |
| LV-MAX™ Enhancer | 40 mL | 2–8°C, protect from light |
- Sufficient for 1 L of lentivirus production.
- Do not freeze to maintain reagent stability.
Specifications
| Property | Details |
|---|
| Cell Line Compatibility | HEK 293-derived Viral Production Cells |
| Culture Type | Suspension Cell Culture |
| Classification | Animal-Origin-Free, Chemically Defined, Protein-Free, Serum-Free |
| Cell Type | HEK 293-derived Cells |
| Sample Type | Plasmid DNA |
| Transfection Method | Lipid-Based Transfection |
| For Use With | Lentivirus Production |
| Product Line | LV-MAX™ |
| Product Type | Transfection Kit |
| Serum Compatibility | Yes |
| Shipping Conditions | Wet Ice |
| Unit Size | Each |
Available Product Variant
| Catalog Number | Quantity |
|---|
| A35348 | 1 L |
Applications
1. Lentiviral Vector Production for Gene Therapy & Research
- Optimized for high-yield lentivirus generation in HEK 293-derived Viral Production Cells.
- Superior to PEI-based transfection in terms of titer yield and reproducibility.
2. Cell & Gene Therapy Development
- Ideal for CAR-T cell engineering and gene delivery applications.
- Supports large-scale transient lentivirus production for biotherapeutics.
3. Bioprocessing & Large-Scale Virus Production
- Compatible with 96-well plates to 2-L bioreactors for scalable manufacturing.
- Designed for consistent and reproducible high-density viral transfection.
Storage & Handling
- Store at 2–8°C, protecting reagents from direct light exposure.
- Do not freeze, as freezing may alter reagent stability.
- Maintain aseptic conditions during handling to prevent contamination.
Ordering Information
| Catalog Number | Description | Quantity |
|---|
| A35348 | Gibco™ LV-MAX™ Transfection Kit | 1 L |
The Gibco™ LV-MAX™ Transfection Kit is an advanced, high-efficiency transfection reagent system designed to maximize lentiviral vector production in suspension HEK 293-derived Viral Production Cells. It provides reproducible, scalable, and high-yield transfection results while ensuring serum-free, chemically defined, and animal-origin-free formulations. This kit is an essential component for gene therapy research, viral vector manufacturing, and bioprocessing applications.
0
